The Week in Review: Suzhou Nanomed Funded by Softbank

Suzhou Natong BioNanotechnology signed a funding agreement with Softbank’s SB China Venture Capital (SBCVC); China exchanges raised more money in IPO transactions during 2009 than the US did; Covance has begun construction on a pre-clinical facility near Shanghai; Sinovac (北京科兴生物制品有限公司) raised $54 million in a secondary offering; NeoStem's China subsidiary was granted SFDA approval for an anti-ulcer drug; Sinobiopharma was given production approval for a blood pressure medication; China Aoxing Pharma completed a Phase III trial of a synthetic oral narcotic; Novo Nordisk submitted its type 2 Diabetes drug for SFDA approval; and Bayer Schering is beginning a Phase IV trial of a blood pressure drug in China. More details... Stock Symbol: (NYSE: CVD) (NSDQ: SVA) (NYSE Amex: NBS) (OTCBB: SNBP) (OTCBB: CAXG) (NYSE: NVO)